OncoSec rises on collaboration with Merck & Co to test skin cancer drug

OncoSec Medical Incorporated

06/07/2021 22:02

** Immunotherapy developer's shares  ONCS.O  up 23% at $3.4
after the bell; set for their best day in 8 months on Wednesday
if gains hold
    ** Co says it has entered into a clinical trial
collaboration with Merck & Co  MRK.N  to test its anti-cancer
gene therapy, Tavo, with MRKS's cancer drug Keytruda in a
late-stage trial to treat patients with skin cancer  urn:newsml:reuters.com:*:nPn1Ns9g5a
    ** Trial will evaluate the overall survival of patients
treated with Tavo in combination with Keytruda versus standard
of care to treat patients with melanoma whose disease did not
respond to initial checkpoint inhibitor therapy 
    ** Trial is expected to support accelerated approval and/or
a full licensure - ONCS
    ** ONCS has fallen 57% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))